‘Risk averse’ rheumatologists report declining JAK use, increased reliance on abatacept

The safety signals for cardiovascular events and malignancy associated with Janus kinase inhibitors in rheumatoid arthritis have led to rheumatologists increasingly reaching for abatacept instead, according to data.
The market analysis firm Spherix Global Insights surveyed 102 rheumatologists through the first quarter of 2022 and found that rheumatologists are increasingly opting for abatacept (Orencia, Bristol Myers Squibb) over JAK inhibitors.
The analysists at Spherix attribute the shift to negative results of the ORAL Surveillance study, which was published in January 2021 and led the FDA

The safety signals for cardiovascular events and malignancy associated with Janus kinase inhibitors in rheumatoid arthritis have led to rheumatologists increasingly reaching for abatacept instead, according to data.
The market analysis firm Spherix Global Insights surveyed 102 rheumatologists through the first quarter of 2022 and found that rheumatologists are increasingly opting for abatacept (Orencia, Bristol Myers Squibb) over JAK inhibitors.
The analysists at Spherix attribute the shift to negative results of the ORAL Surveillance study, which was published in January 2021 and led the FDA